Key events, in time order
Declining option IV alongside institutional interest, but no new factual increment
PAPZIMEOS Q2 营收为 $53.1 million，较 Q1 的 $21.6 million 增长超过 145%，上市至今累计营收超过 $78 million。
Launch beats expectations, but cash tied up in receivables
患者中心注册约400名患者，其中25%来自社区医疗机构。
None yet
None yet
The discussion focuses on $PGEN as an option with increasing implied volatility, suggesting potential price movement or speculative interest.
Main discussion
No comments yet.
Facts and opinions separated · All items sourced · Not investment advice
Precigen builds gene and cell therapies using proprietary DNA engineering tools, plus genetically modified pigs for regenerative medicine. Think of it as a biotech toolkit maker selling both treatments and the tech behind them.
Money comes from licensing its platforms like UltraVector and AdenoVerse to partners such as Alaunos Therapeutics and Oragenics. Revenue is tiny (USD 0.01B annually) with negative net margins, so it's pre-commercial and burning cash.
Its patented gene-editing and delivery systems (Sleeping Beauty, RheoSwitch) are hard to replicate, and partners like Castle Creek pay for access. But competition from CRISPR-focused firms like Editas Medicine and Intellia Therapeutics is eroding its different
Strong Buy (sector percentile 96) — value D, growth A+, profitability C-, momentum A-, revisions A. Updated daily, sector-relative, identical for every user.
